Results 121 to 130 of about 750,934 (136)
Some of the next articles are maybe not open access.

PD-1/PD-L1 in Disease

Immunotherapy, 2017
Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor ...
Kuol, Nyanbol   +3 more
openaire   +3 more sources

Revisiting PD-1 signaling

Science Signaling, 2018
The protective effect of anti-PD1 therapy in cancer may not require the phosphatase Ptpn11.
openaire   +1 more source

Anti–PD-1 Therapy in Melanoma

Seminars in Oncology, 2015
Immune-regulatory mechanisms are used by cancer to hide from the immune system. Advances and in-depth understanding of the biology of melanoma and its interaction with the immune system have led to the development of some of antagonistic antibodies to the programmed death 1 pathway (PD-1) and one of its ligands, programmed death ligand 1 (PD-L1), which
Blanca, Homet Moreno   +3 more
openaire   +2 more sources

MICRO-MELT PD#1

Alloy Digest, 2004
Abstract Micro-Melt PD#1 alloy is a powder metallurgically processed air hardening die steel with wear resistance better than AISI D2 while maintaining good toughness. This datasheet provides information on composition, physical properties, hardness, and elasticity.
openaire   +1 more source

Glucocorticoids and PD-1

Science Signaling, 2018
Signaling by the glucocorticoid receptor in NK cells induces expression of the checkpoint inhibitor PD-1 to prevent immunopathology.
openaire   +1 more source

Tumor Immunotherapy Directed at PD-1

New England Journal of Medicine, 2012
The treatment of cancer by harnessing immune responses has long been pursued. Efforts to turn on the immune system against cancers with inactivated tumor vaccines or intratumor injections of bacterial products to induce local inflammation and recruit an antitumor immune response have led to anecdotal successes. Increasing knowledge about how the immune
openaire   +2 more sources

PD-1

1997
A. Neil Barclay   +5 more
openaire   +1 more source

PD-1-Antikörper

Der Hautarzt, 2012
openaire   +1 more source

PD-1

2018
openaire   +1 more source

Home - About - Disclaimer - Privacy